Oxcarbazepine

Oxcarbazepine

SCHEMBL35129

NC(=O)N1c2ccccc2CC(=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A

The experimentally established mechanism targets of Oxcarbazepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN4A known ✓ P35499 1/20 0.46
SCN5A known ✓ Q14524 1/20 0.46
SCN9A known ✓ Q15858 1/20 0.46
KDM4E B2RXH2 4/20 1.00
ALDH1A1 P00352 4/20 1.00
CYP3A4 P08684 2/20 1.00
MAPT P10636 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
PABPC1 P11940 1/20 1.00
BLM P54132 1/20 1.00
NOTUM Q6P988 2/20 0.49
LMNA P02545 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
BCHE P06276 2/20 0.45
ACHE P22303 1/20 0.45
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HDAC1 Q13547 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxcarbazepine SCHEMBL29359799 1.00 KDM4E (1.00) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL4655725 1.00 KDM4E (1.00) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL29433241 1.00 KDM4E (1.00) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL27944289 0.98 KDM4E (0.97) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL17372732 0.98 KDM4E (0.97) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL5652834 0.94 KDM4E (0.89) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL29123953 0.94 ALDH1A1 (0.89) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL2885435 0.94 KDM4E (0.89) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL321371 0.92 KDM4E (0.84) KDM4EALDH1A1CYP3A4MAPTMEN1
Oxcarbazepine SCHEMBL2328082 0.92 KDM4E (0.84) KDM4EALDH1A1CYP3A4MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 18489 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
US-20260137654-A1 COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER THE REGENTS OF THE UNIV OF CALIFORNIA (US) 2026-05-21 US claimed
CN-122038556-A Method for predicting sodium valproate therapeutic response based on TPH2 gene polymorphism, kit and application thereof 深圳市宝安区妇幼保健院 2026-05-15 CN claimed
CN-120622619-B Method for treating dibenzo organic pollutants in water body 广东省科学院生态环境与土壤研究所 2026-05-12 CN claimed
US-20260124211-A1 COMPOSITION CONTAINING LAMOTRIGINE, AND PREPARATION METHOD AND USE THEREOF SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) 2026-05-07 US claimed
EP-4736841-A1 A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT IQ medical GmbH (DE) 2026-05-06 EP claimed
US-12595237-B2 Lamotrigine hydrate crystal form, preparation method therefor, and composition containing same SHANGHAI AUCTA PHARMACEUTICALS CO., LTD. (CN) 2026-04-07 US claimed
US-12594256-B2 A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy ANAVEX LIFE SCIENCES CORP. (US) 2026-04-07 US claimed
US-20260092932-A1 METHODS AND COMPOSITIONS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER THE JOHNSON CENTER FOR CHILD HEALTH AND DEV (US) 2026-04-02 US claimed
EP-4288042-B1 COMBINATION THERAPY FOR TREATING EXECUTIVE FUNCTION DISORDERS ANAKA PHARMACEUTICALS INC (US) 2026-04-01 EP claimed
WO-1995029665-A1 EFFECTIVE DOSAGE FORM FOR ANTIEPILEPTIC DRUGS ALZA CORPORATION (US) 1995-11-09 WO claimed
EP-0646374-A1 Double-coated oxcarbazepine containing tablets CIBA-GEIGY AG (CH) 1995-04-05 EP claimed
US-4559174-A NITRATION, REDUCTION AND HYDROLYSIS OF 5-CYANO5H-DIBENZ/B,FLAZEPINE CIBA GEIGY CORPORATION (US) 1985-12-17 US claimed
EP-0028028-B1 PROCESSES FOR THE PREPARATION OF AN OXO COMPOUND, AND INTERMEDIATES REQUIRED THEREFOR CIBA-GEIGY AG (CH) 1985-05-22 EP claimed
EP-0050589-B1 PHARMACEUTICAL COMPOSITIONS WITH AN ANTI-EPILEPTIC AND ANTI-NEURALGIC EFFECT, AND PROCESS FOR THEIR MANUFACTURE CIBA-GEIGY AG (CH) 1984-09-12 EP claimed
US-4452738-A Process for the manufacture of 5-carbamoyl-10-oxo-10,11-dihydro-5H-dibenz[b,]azepine CIBA-GEIGY CORPORATION (US) 1984-06-05 US claimed
US-4431641-A AN ANTICONVULSANT DIBENZ/B,F/AZEPINE POTENTIATED BY A VINCAMINE OR PIRACETAM DERIVATIVE CIBA-GEIGY CORPORATION (US) 1984-02-14 US claimed
US-4409212-A Method of preventing and treating cerebral insufficiency CIBA-GEIGY CORPORATION (US) 1983-10-11 US claimed
EP-0050589-A1 Pharmaceutical compositions with an anti-epileptic and anti-neuralgic effect, and process for their manufacture CIBA-GEIGY AG (CH) 1982-04-28 EP claimed
EP-0028028-A2 Processes for the preparation of an oxo compound, and intermediates required therefor CIBA-GEIGY AG (CH) 1981-05-06 EP claimed